查看“Daraxonrasib”的源代码

{{Infobox drug
| drug_name         = Daraxonrasib
| image             = | caption           = Daraxonrasib 化学结构
| type              = small_molecule
| ALIASES           = RMC-6236
| CAS_number        = 2765081-21-6
| PubChem           = 164726578
| DrugBank          = 
| UNII              = B6T47Y2UAP
| chemical_formula  = {{Chembox formula|C=44|H=58|N=8|O=5|S=1}}
| molecular_weight  = 811.06 g/mol
| legal_status      = Investigational
| legal_status_desc = (研究性药物)
| routes_of_administration = [[口服]]
| class             = [[RAS抑制剂]]<br>(RAS(ON) Multi-selective Inhibitor)
| developer         = [[Revolution Medicines]]
}}

'''Daraxonrasib'''（研发代号：'''RMC-6236'''）是一种口服的、强效的、多选择性 [[RAS蛋白|RAS]](ON) 抑制剂，由 [[Revolution Medicines]] 公司开发。它是一种具有创新机制的“三复合物”（Tri-complex）抑制剂，主要用于治疗携带 RAS 突变（如 [[KRAS]]、[[NRAS]] 或 [[HRAS]] 的 G12X、G13X、Q61X 突变）的恶性肿瘤，包括[[胰腺导管腺癌]] (PDAC)、[[非小细胞肺癌]] (NSCLC) 和[[结直肠癌]] (CRC)<ref name="Nature2024">{{cite journal | vauthors = Nichols RJ, et al. | title = RMC-6236, a first-in-class, RAS-selective, oral tri-complex RASMULTI(ON) inhibitor | journal = [[Nature (journal)|Nature]] | date = 2024-04 | volume = 629 | issue = 8014 | pages = 917–924 | doi = 10.1038/s41586-024-07379-w | pmid = 38599307 }}</ref>。

== 临床研究 ==
Daraxonrasib 目前处于临床开发阶段。在早期的 I/Ib 期临床试验（RMC-6236-001）中，该药物在经治的 KRAS 突变晚期实体瘤患者中显示出了初步疗效和可控的安全性<ref name="ESMO2023">{{cite journal | vauthors = Arbour KC, et al. | title = Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) | journal = [[Annals of Oncology]] | date = 2023-10 | volume = 34 | issue = Supplement 2 | pages = S458 | doi = 10.1016/j.annonc.2023.09.1838 }}</ref>。

== 参考资料 ==
{{reflist}}

[[Category:RAS抑制剂]]
[[Category:抗肿瘤药]]
[[Category:在研药物]]